These drugs target some of the most pressing cancer types, including multiple myeloma, breast cancer, and bladder cancer ...

Retifanlimab-dlwr (Zynyz) has been granted approval from the FDA for treatment of locally recurrent or metastatic squamous ...

Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ...

The FDA has approved Zynyz as a first-line treatment in combination with chemo and as a single-agent following progression in ...

With significant survival improvements seen, the FDA has granted approval to retifanlimab for the first-line treatment of ...

Efti plus Keytruda and chemo achieved a 61% response rate in first-line advanced non-squamous non–small cell lung cancer, ...

Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. | ...

Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L ...

Merck (MRK) stock gains as its bestselling drug, Keytruda, as part of a combination regimen, succeeds in a Phase 3 trial for ...

Biotech investors are preparing for what may be the most important clinical trial readout for them this summer.

This drugmaker achieved a milestone - its first quarterly profit. But the stock is down despite the good tidings.

Corporate R&D event highlighted positive ACR-368 data in endometrial cancer patients who had all received prior anti-PD-1 and platinum-based chemotherapy Confirmed overall response rate (cORR) of 35% ...